Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABIMMUNE: Durvalumab + Tremelimumab + SBRT in Metastatic Squamous Cell Carcinoma
NCT03212469Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jun 2017
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in head and neck squamous cell carcinoma (HNSCC), lung cancer, esophageal cancer, sponsored by Gustave Roussy. Started Jun 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)lung canceresophageal cancer
Beyond the preview
Go deeper on NCT03212469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212469.